World Heart Federation Cholesterol Roadmap 2022
Source : https://globalheartjournal.com/article/10.5334/gh.1154/
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death globally despite major advances in our understanding of the pathophysiology of atherosclerosis, its consequences and the development of new preventive...
Conclusions: The adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated...
Share
Equivalent Impact of Elevated Lipoprotein(a) and Familial Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease
Source : https://www.sciencedirect.com/science/article/abs/pii/S0735109722069546?via=ihub
Genetically elevated plasma lipoprotein(a) and familial hypercholesterolemia each result in premature atherosclerotic cardiovascular disease (ASCVD); however, a direct comparison in the same population is needed of these 2 genetic traits...
Conclusions: Lipoprotein(a) levels equivalent to LDL cholesterol in clinical and genetic familial hypercholesterolemia were 67 to 402 mg/dL and 180 mg/dL, respectively, for myocardial infarction and 130 to 391 mg/dL and 175 mg/dL, respectively, for ASCVD.
Share
High-Intensity Statin With Severe Consequences: A Case of Non-autoimmune Rosuvastatin-Induced Myonecrosis
Statins constitute a cornerstone in the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). The routine use of these lipid-lowering agents may lead to unintentional neglect of their well-known...
Conclusions/Relevance: Ultimately, statin-induced myopathy may significantly hinder activities of daily living and impair quality of life. It is, however, a reversible condition if diagnosed and appropriately managed early on. Clinicians are encouraged to acquaint themselves with the symptomatology and relevant laboratory values that commonly...
Share
Screening and Management of Dyslipidemia in Children and Adolescents - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36362707/
This review provides an overview of pediatric dyslipidemia emphasizing screening and treatment recommendations. The presence of risk factors for cardiovascular disease in childhood poses significant risk for the development of...
Conclusion/Relevance: Treatment of pediatric dyslipidemia begins with lifestyle modifications, but primary genetic dyslipidemias may require medications such as statins. As pediatric lipid disorders often have genetic or familial components, it is important that all physicians are aware that cardiovascular risk begins in childhood, and can both...
Share
Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease
Source : https://www.lipidjournal.com/article/S1933-2874(22)00286-0/fulltext
In a previous study, we used a Monte Carlo simulation model to estimate the proportion of patients with atherosclerotic cardiovascular disease (ASCVD) who would require various lipid-lowering therapies (LLTs), and...
Conclusions: Evinacumab may be useful to address such unmet needs effectively, as the majority of those not at goal after PCSK9 inhibitors could achieve the goal of
Share